C14-490

C14-490 LNPs CD45 antibody conjugation to C14-490 LNPs increases average particle diameter by ~20 nm without altering PDI or mRNA encapsulation efficiency^[1].
C14-490 LNPs conjugated to CD45 antibody (100 ng total mRNA, 24 h incubation) boost GFP mRNA delivery efficiency eightfold in Jurkat cells; 24 h administration of 100 ng mRNA leads to 35% GFP+ cells with no decline in cell viability^[1].

C14-490 LNPs conjugated to CD45 antibody (25-150 ng total mRNA; 24 h) exhibit dose-dependent improvement in mRNA delivery to Jurkat cells, with maximum 10-fold enhancement at 50 ng mRNA per 30,000 cells after 24 h incubation^[1].
C14-490 LNPs conjugated to CD45 antibody (100 ng total mRNA for Jurkat cells, 25 ng total mRNA for HepG2 cells; 24 h transfection, 30 min antibody pre-incubation) have enhanced mRNA delivery efficacy that is CD45 receptor-specific, as pre-treatment with free CD45 antibodies blocks the effect, and no enhancement is observed in CD45-negative HepG2 cells^[1].
C14-490 ionizable lipid formulated into LNPs exhibit consistent size, low polydispersity, and high encapsulation efficiency^[1].
C14-490 ionizable lipid in LNPs correlates with enhanced relative GFP knockout efficacy in HepG2-GFP cells, with a positive correlation coefficient of +0.34^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.